Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
02:06pm, Tuesday, 28'th Apr 2026
Intellia shares drop 4% despite phase III data meeting all endpoints. The company begins a rolling FDA filing.
Intellia Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 27'th Apr 2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript
Wall Street on Edge Ahead of Next U.S.-Iran Development
12:05pm, Monday, 27'th Apr 2026
Stocks are lower across the board, as investors await the latest U.S.-Iran developments and monitor oil prices
Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test
10:07am, Monday, 27'th Apr 2026
Intellia Therapeutics Inc. (NASDAQ:NTLA) shares are up on Monday after the company announced a rolling BLA submission to the FDA for its gene-editing therapy, lonvo-z (NTLA-2002), which is aimed at tr
Stock Futures Subdued by Geopolitical Uncertainty
09:11am, Monday, 27'th Apr 2026
Stock futures are struggling this morning as investors await Magnificent Seven earnings and the Fed meeting
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
07:06am, Monday, 27'th Apr 2026
Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.
3 Biotech Stocks That Could Benefit from the Patent Cliff
07:06am, Monday, 27'th Apr 2026
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
07:01am, Monday, 27'th Apr 2026
Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition succeeded in a Phase 3 trial, a landmark for gene editing. The treatment uses Nobel Prize-winning Crispr technology
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
07:00am, Monday, 27'th Apr 2026
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from bo
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Massachusetts Financial Services Co. MA Makes New $318,000 Investment in Intellia Therapeutics, Inc. $NTLA
04:26am, Sunday, 19'th Apr 2026
Massachusetts Financial Services Co. MA bought a new position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in the fourth quarter, according to the company in its most recent Form 13F filing with the
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
10:36am, Thursday, 16'th Apr 2026
Intellia stock climbs nearly 20% in three months as pipeline progress, lifted FDA holds, and late-stage study updates boost investor optimism.
2 Healthcare Stocks to Buy and 1 to Approach With Caution
05:00pm, Wednesday, 15'th Apr 2026
Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.
